bluebird bio (NASDAQ:BLUE) insider David Davidson sold 3,000 shares of bluebird bio stock in a transaction dated Thursday, April 12th. The stock was sold at an average price of $180.17, for a total value of $540,510.00. Following the completion of the sale, the insider now directly owns 27,905 shares of the company’s stock, valued at approximately $5,027,643.85. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
David Davidson also recently made the following trade(s):
- On Monday, April 2nd, David Davidson sold 22,000 shares of bluebird bio stock. The stock was sold at an average price of $167.52, for a total value of $3,685,440.00.
- On Friday, February 2nd, David Davidson sold 4,000 shares of bluebird bio stock. The shares were sold at an average price of $202.36, for a total value of $809,440.00.
Shares of NASDAQ:BLUE opened at $168.25 on Tuesday. bluebird bio has a 1 year low of $74.45 and a 1 year high of $236.17.
Large investors have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. boosted its stake in bluebird bio by 2,110.3% during the fourth quarter. Meeder Asset Management Inc. now owns 641 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 612 shares during the last quarter. NuWave Investment Management LLC bought a new position in bluebird bio during the fourth quarter valued at approximately $135,000. Ladenburg Thalmann Financial Services Inc. boosted its stake in bluebird bio by 454.2% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock valued at $136,000 after buying an additional 813 shares during the last quarter. D.A. Davidson & CO. bought a new position in bluebird bio during the fourth quarter valued at approximately $214,000. Finally, Quinn Opportunity Partners LLC bought a new position in bluebird bio during the fourth quarter valued at approximately $232,000.
A number of analysts have recently issued reports on BLUE shares. Oppenheimer reiterated a “hold” rating on shares of bluebird bio in a research report on Tuesday, January 9th. BidaskClub downgraded bluebird bio from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 16th. Leerink Swann downgraded bluebird bio from an “outperform” rating to a “market perform” rating and boosted their target price for the stock from $162.00 to $194.00 in a research report on Thursday, January 25th. Canaccord Genuity restated a “buy” rating and issued a $250.00 target price on shares of bluebird bio in a research report on Thursday, February 1st. Finally, Cantor Fitzgerald reaffirmed a “sell” rating and issued a $113.00 price target (down from $122.00) on shares of bluebird bio in a research note on Wednesday, February 21st. Four equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $195.65.
ILLEGAL ACTIVITY WARNING: “bluebird bio (BLUE) Insider David Davidson Sells 3,000 Shares of Stock” was first posted by Week Herald and is the sole property of of Week Herald. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://weekherald.com/2018/04/24/bluebird-bio-inc-blue-insider-david-davidson-sells-3000-shares-of-stock.html.
bluebird bio Company Profile
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.